Graduation from the Russell 2000 to the R1000 is a significant milestone, reflecting the company’s sustained growth and suggesting the market recognizes the scale and maturity of its commercial outlook and late-stage pipeline.
BridgeBio was a leader in the R2000 before its promotion, with a market cap of more than $13 billion, roughly 12 times the index median. Its move to the Russell 1000 was not unexpected, and analysts had indicated in early June that the $13 billion-plus market-cap firm had outgrown the small-cap index.
The Russell Index reconstitution is a once-a-year process in which FTSE Russell reviews the US equity market and reshuffles companies across its indices.
On June 29, a Bank of America analyst maintained their Buy rating on BridgeBio, assessing a potential 40.26% growth over the next year.
Graduation to the R1000: what does it mean for BridgeBio?
Before the reconstitution, analysts at Mizuho described the move as “long-term positive” for BridgeBio’s stock because it expands the company’s “investable universe”.
A wider investable universe means BridgeBio becomes eligible for larger pools of institutional capital, increasing demand for its shares, improving liquidity and giving the company greater visibility among long-only investors.
Since 30 June 2025, BridgeBio stock is up more than 66%, and promotion to the R1000 is expected to drive this growth even further.
Analysts have pointed to some short-term selling pressure around reconstitution, but noted that this could create an attractive entry point for investors and was purely technical.
The more important point for stock pickers is that BridgeBio’s solid fundamentals continue to strengthen.
Acoramidis (Attruby) underpins BridgeBio’s bullish stock case
Acoramidis, marketed as Attruby, is BridgeBio’s FDA-approved treatment for adults with cardiomyopathy caused by wild-type or variant transthyretin-mediated amyloidosis.
Attruby generated $362.4 million in net product revenue in its first full year on the market, and BridgeBio reported $502.1 million in full-year 2025 revenue. The drug’s launch trajectory also supports the bullish view taken by analysts.
By February 2026, BridgeBio said Attruby had generated 7,804 unique patient prescriptions from 1,856 unique prescribers since FDA approval in November 2024.
BridgeBio also remains less exposed than Alnylam to the CARDIO-TTransform readout, because investor debate around BridgeBio is more focused on first-line share for Acoramidis versus Pfizer’s tafamidis and the company’s broader revenue diversification.
US and European ATTR-CM market major opportunity for BridgeBio
Analysts have forecast peak annual sales for Attruby of more than $3 billion, and the ATTR-CM treatment market is projected to reach $16.5 billion by 2030.
International expansion holds commercial promise for BridgeBio too. Acoramidis is sold in Germany by Bayer and marketed as Beyonttra. The next European launch of Acoramidis is expected to be Denmark, with other markets expected to follow, including France, Spain, Italy, and more.
Attruby results remain impressive. BridgeBio has said that Attruby provides near-complete TTR stabilization and has shown rapid clinical benefit, securing a strong position in the market against competitors Pfizer and Alnylam.
Strong pipeline supports bullish assessment of BridgeBio
BridgeBio’s pipeline adds further upside potential, strengthening the bullish case for the California biopharmaceutical company.
BridgeBio has reported three positive Phase 3 readouts in recent months and is advancing programs including BBP-418 for limb-girdle muscular dystrophy type 2I/R9, encaleret for autosomal dominant hypocalcemia type 1, and oral infigratinib for achondroplasia.
BBP-418 has received Priority Review and encaleret has been submitted to the FDA.
According to a study published in the New England Journal of Medicine on June 28th, BridgeBio’s achondroplasia drug infigratinib boosts growth in children and significantly boosts body proportionality. This is a finding that analysts say could set the pill apart from competitors for treating the most common cause of dwarfism. BridgeBio plans to file a regulatory package for infigratinib in the third quarter of this year, with a potential launch “in early to mid 2027.”
This gives BridgeBio a stronger profile than many single-product biotechnology companies, making it a compelling investment opportunity.
Key Takeaway: Why analysts are bullish on BridgeBio
BridgeBio has a rapidly growing commercial asset (Acoramidis), a large market opportunity in ATTR-CM, and several late-stage drugs that could broaden its revenue base if approved.
The Russell 1000 promotion has reinforced investor confidence in the commercial stage biopharmaceutical company that has demonstrated growing revenue, increasing visibility, and multiple revenue catalysts ahead.
For biopharma watchers and stock pickers, BridgeBio is a bullish stock worth keeping a close eye on.
What is BridgeBio?
BridgeBio is a commercial-stage biopharmaceutical company founded in 2015 and headquartered in Palo Alto, California.
It operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.
BridgeBio was co-founded in 2015 by Neil Kumar, Ph.D., Frank McCormick, Ph.D., and Andrew Lo, Ph.D., among others.
BridgeBio’s pipeline also includes investigational drugs which aim to treat the following conditions: Hypochondroplasia, Early-Stage Variant Transthyretin Amyloidosis, Chronic Hypoparathyroidism-NIH IIR, and Canavan disease.
In May 2026, BridgeBio presented late-stage data which showed patients taking Attruby had a 34% lower rate of cardiovascular hospitalizations than those on tafamidis, Pfizer’s ATTR-CM treatment which is sold under the name Vyndamax. These figures come from an indirect, matched comparison.
